Discussion
MIL62, a treatment approved in China to treat neuromyelitis optica spectrum disorder (NMOSD), was superior to a placebo at preventing relapses and controlling disease activity in people with the autoimmune disease. That’s according to data from the Phase 3 portion of a China-based Phase 1b/3 clinical trial…